Summary of the UKHSA and MHRA information received about the H5 Avian Influenza Vaccine.

A long read

Modified from Al Nisbet

Before Christmas, we started a series of FOI requests to clarify how taxpayers' money is spent on pandemic preparedness. We were responding to the news that the UKHSA had purchased 5,147,670 doses of an Influenza H5 “pandemic” vaccine from CSL/Sequirus Ltd.

We were unconvinced by the evidence of a threat from avian influenza produced by the UKHSA.

The UKHSA review of influenza H5N1 Incubation and Infectiousness

So, we investigated the product, which was not named in the UKHSA announcement, and found a 17-to-1 vaccine-to-placebo ratio of deaths and the Risk Management Plan written by Sequirus and approved by EMA. On page 21, it mentions all the rare neurological harms observed in the 2009 Pandemrix roll out, plus vasculitis.

The H5N1 vaccine UKHSA purchased from CSL/Sequirus LTD

Perhaps someone in EMA has a memory as long as ours.

We grouped our questions into six sets to try and dodge the £450 limit on requests.  The questions are listed here:

FOI Questions for the UKHSA on WhatDoTheyKnow

We sent the request under the FOIA via the platform WhatDoTheyKnow.

Over two months later, this is how far we have got.

Question 1 Information on…